SPTX Stock News & Catalysts

FEATURED

Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Announced positive topline data from Phase 1 driving simulation trial of GlyphAllo™, showing that GlyphAllo did not impair next-morning driving performance compared to placebo Dosed first patient in Phase 2a trial of

Summary

Nov 2, 2026, 7:00 AM ·Business Wire

RECENT

Seaport Therapeutics to Present at Stifel 2026 Healthcare Conference

Seaport Therapeutics, Inc. (NASDAQ:SPTX) ("Seaport" or the "Company"), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced its

Oct 28, 2026, 7:00 AM ·Business Wire

PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress

PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded

Oct 9, 2026, 1:00 PM ·Business Wire

Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress

First scientific presentation of detailed PK data demonstrates dose-dependent increases in agomelatine exposure, no food effect, and no accumulation of exposure over seven days of dosing Detailed data reinforces

Oct 9, 2026, 7:00 AM ·Business Wire

PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance

Oct 7, 2026, 1:00 PM ·Business Wire

Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance

Trial is designed to demonstrate proof-of-pharmacology by evaluating the effects of GlyphAgo on sleep and anxiety symptoms in patients with generalized anxiety disorder In Phase 1, GlyphAgo demonstrated a

Oct 7, 2026, 7:00 AM ·Business Wire

Seaport Therapeutics to Participate in September Investor Conferences

Seaport Therapeutics, Inc. (NASDAQ:SPTX) ("Seaport" or the "Company"), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that

Sep 14, 2026, 7:00 AM ·Business Wire

PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

Sep 9, 2026, 1:13 PM ·Business Wire

Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

Trial met its primary endpoint, showing that evening dosing of GlyphAllo at 375 mg did not impair next-morning driving performance compared to placebo on Day 5, following multiple-day dosing Key secondary endpoint

Sep 9, 2026, 7:00 AM ·Business Wire

Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference

Seaport Therapeutics, Inc. (NASDAQ:SPTX) ("Seaport" or the "Company"), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that

Aug 31, 2026, 7:00 AM ·Business Wire

Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Enrollment in Phase 2b BUOY-1 trial of GlyphAllo™ in major depressive disorder (MDD) is on track with topline data expected in 1H 2027 Phase 1 driving simulation trial of GlyphAllo on track to report topline data in

Aug 3, 2026, 7:00 AM ·Business Wire

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

Jun 9, 2026, 2:00 AM ·Business Wire

Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

New data from Phase 1 trial of GlyphAgoTM build upon previously reported topline data and further demonstrate GlyphAgoTM can achieve therapeutic exposures of agomelatine at doses projected to avoid liver enzyme

Jun 8, 2026, 7:05 AM ·Business Wire

Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

Repeat dosing of GlyphAgo confirms favorable safety, tolerability, and pharmacokinetics observed across the Phase 1 program, with no liver-related adverse events observed New data demonstrate seven-day dosing of

Jun 8, 2026, 7:00 AM ·Business Wire

Seaport Therapeutics to Participate in Two Upcoming Investor Conferences

Seaport Therapeutics, Inc., (NASDAQ:SPTX) ("Seaport" or the "Company"), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that members of its

Jun 1, 2026, 7:00 AM ·Business Wire

Seaport Therapeutics, Inc. Common Stock SPTX · News